多西紫杉醇联合吡柔比星膀胱灌注对晚期膀胱癌预后及生存质量的影响

Docetaxel Pirarubicin intravesical impact on advanced bladder cancer prognosis and quality of life

目的 探讨多西紫杉醇联合吡柔比星膀胱灌注治疗对晚期膀胱癌患者的预后与生存质量的影响.方法 选取本院2009年1月-2009年12月的80例晚期膀胱癌患者为研究对象,将其按照随机数字表法分为联合组与对照组,均40例.对照组应用吡柔比星膀胱灌注治疗,联合组应用多西紫杉醇、吡柔比星膀胱灌注治疗,观察两组患者的预后与生存质量变化.结果 联合组患者近期临床治疗总有效率、3年后生存率和5年后生存率分别为82.5％、67.5％、52.5％,明显的高于对照组的52.5％、50.0％、37.5％,差异有统计学意义（P＜0.05）.治疗后两组的评分较治疗前有明显的提高,且联合组优于对照组,差异有统计学意义（P＜0.05）.结论 临床中对于晚期膀胱癌患者实施多西紫杉醇、吡柔比星膀胱灌注治疗效果显著,改善患者的预后,提高其生存质量,值得临床中应用.

Objectives To explore the impact of intravesical docetaxel pirarubicin on the prognosis and quality of life for patients with advanced bladder cancer.Methods A total of 80 hospitalized patients with advanced bladder cancer during January-December 2009 were randomly divided into combination and control groups（n =40 each）.The control group received intravesical pirarubicin chemotherapy while the combination group had additional docetaxel.Their prognosis and quality of life were compared.Results For two groups,the clinical total efficiency,3-year survival rate after 5-year survival rate were 82.5%,67.5%,52.5% versus 52.5%,50.0%,37.5% respectively.And the differences was statistically significant （P 〈 0.05）.Conclusions For advanced bladder cancer,a combination treatment of docetaxel and intravesical pirarubicin may significantly improve the prognosis and quality of life.And further promotions are warranted.